Assembly Biosciences, Inc. (ASMB)
ASMBNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$21.29
+0.1700 (+0.80%) today
Closed, Nov 16, 4:00 PM ET
- Market cap
- $432.48m
- P/E
- 26.3
- EPS, last 4 quarters
- $0.8100
- Dividend yield
- –
- Day range
- –
- 52-week range
- $19.20 to $39.71
- Average volume
- –
- Previous close
- $21.12
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $48.50, +127.8% from here
Earnings
next estimate $3.19Next report
Dec 2025
+586.3%
Mar 2026
+26.0%
Jun 2026
+71.4%
Sep 2026
-111.4%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $42.47m | $8.21m | $13.37m | $2.96m |
| Gross profit | $42.47m | $8.21m | $13.37m | $2.96m |
| Operating income | $19.80m | -$11.37m | -$6.34m | -$23.41m |
| Net income | $22.09m | -$9.08m | -$3.86m | -$20.26m |
Last four quarters: revenue $67.01m, margin -16.6%, free cash flow –
News
8 latest- Assembly Biosciences, Inc. Reports Third Quarter 2026 Financial Results and Recent UpdatesFintel · 4 days ago
- Assembly Biosciences (ASMB) Reports Q3 Loss, Lags Revenue EstimatesZacks · 4 days ago
- Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue EstimatesZacks · 5 days ago
- Amphastar Pharmaceuticals (AMPH) Tops Q3 Earnings and Revenue EstimatesZacks · Nov 5, 2026
- Best Momentum Stocks to Buy for September 17thZacks · Sep 17, 2026
- New Strong Buy Stocks for September 17thZacks · Sep 17, 2026
- Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive PicksZacks · Sep 9, 2026
- Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy ServicesZacks · Sep 8, 2026
The company
Assembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule therapeutics aimed at advancing the treatment paradigm of serious viral and liver diseases and improving the lives of patients worldwide. Led by an accomplished leadership team in antiviral and liver disease drug development, Assembly Bio is committed to improving outcomes for people living with the chronic impacts of herpesviruses, hepatitis delta virus (HDV) infections, cholestatic liver diseases and hepatitis B virus (HBV).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- assemblybio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.